MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Dilution

    Reduction in existing shareholder ownership when new shares are issued.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Dilution is the percentage decrease in an existing shareholder's ownership stake caused by the issuance of new shares - through a financing, option grants, SAFE conversion, or warrant exercise.
    What the regulation says
    While dilution primarily concerns investment and finance, it can indirectly impact MedTech regulatory and quality aspects. For instance, significant changes in ownership structure due to dilution might trigger re-evaluation of the designated authorized representative for EU MDR compliance, or impact resource allocation for maintaining a robust quality management system under 21 CFR 820. Changes in company control could also necessitate reviewing data privacy agreements under HIPAA or GDPR if new entities gain access to patient data.

    What this means in practice

    MedTech companies typically dilute 20–25% per priced round. Founders who raise 6–8 rounds before exit can end up with single-digit ownership. Capital-efficient milestones - anything that lets you raise less or at higher valuations - directly preserve founder equity.

    Examples

    • A MedTech startup undergoes a Series B funding round, diluting existing shareholders to fund a critical clinical trial required for FDA premarket approval (PMA).
    • A company's ownership structure changes significantly after a large equity investment, leading to a re-evaluation of the notified body contract under the EU MDR requirements.
    • New investors join a medical device company through share issuance, prompting a review of the budget allocated for maintaining ISO 13485 certification and post-market surveillance activities.
    Common pitfalls
    • •Confusing financial dilution with product-related dilution, which refers to reducing the concentration of a substance.
    • •Underestimating how dilution affects long-term strategic decisions, including budget allocation for regulatory affairs and quality assurance.
    • •Failing to consider the impact of ownership changes on existing regulatory submissions and approvals, such as marketing authorizations or notified body certifications.
    • •Overlooking the potential for new investors to influence risk management strategies, thereby impacting compliance with ISO 14971.
    • •Not adequately communicating ownership changes to relevant regulatory bodies when such changes affect legal manufacturer status or authorized representation.

    Frequently asked questions

    While dilution doesn't directly alter the technical content of a regulatory submission, significant ownership changes may require updating administrative sections, particularly those identifying the legal manufacturer or authorized representative. This could be relevant for submissions to the FDA or under the EU MDR.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    Carta·1PitchBook·1NVCA·1
    1. 1
      Carta: founder dilution
      Verified
      Cartacarta.com
    2. 2
      PitchBook - MedTech Coverage
      Verified
      PitchBookpitchbook.com
    3. 3
      NVCA Model Documents
      Verified
      NVCAnvca.org

    Inline markers like [1] jump to the matching reference above.